TICKERNERD
Menu
PEPGPEPGHealthcare · Biotechnology

PEPG Stock Forecast: PepGen Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.99
+0.34% on the day

The 8 Wall Street analysts covering PepGen Inc. hold a median 12-month price target of $11 — +251.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 15 Aug 2026 — in the lower half.

Market cap
$206.8M
Ticker Nerd rank
43 / 100
Median analyst target
$11
Analysts covering
8
Total return, dividends reinvested
1W
+4.9%
1M
+22.5%
YTD
−54.1%
1Y
+131.8%
From 52W high
−58.3%
From 52W low
+157.8%
$1.16
$7.17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PEPG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PepGen Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
81
Size
68
Momentum
54
Revisions
52
Issuance
42
Accruals
40
Volatility
38
Quality
37
Value
24

Growth (81): Sales and profits are climbing, and climbing faster than before.

Value (24): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PEPG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PEPG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26PEPGHigh $20Median $11Low $3

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy0 Hold1 Sell
Low $3Median $11High $20

The green dot is the last close — the median target sits +251.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 June 2026Craig-HallumInitiatesBuy$11
13 May 2026WedbushMaintainsOutperform—
1 Apr 2026WedbushMaintainsOutperform—
31 Mar 2026WedbushMaintainsOutperform—
25 Feb 2026OppenheimerInitiatesOutperform—
18 Feb 2026GuggenheimMaintainsBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
27 Oct 2025HC Wainwright & Co.MaintainsBuy—
30 Sept 2025WedbushMaintainsOutperform—
25 Sept 2025HC Wainwright & Co.MaintainsBuy—
25 Sept 2025StifelMaintainsBuy—
25 Sept 2025WedbushMaintainsOutperform—
24 Sept 2025GuggenheimReiteratesBuy—
9 Sept 2025GuggenheimInitiatesBuy—
29 May 2025HC Wainwright & Co.MaintainsBuy—
9 May 2025HC Wainwright & Co.MaintainsBuy—
24 Feb 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.MaintainsBuy—
16 Dec 2024B of A SecuritiesDowngradeUnderperform—
18 Nov 2024B of A SecuritiesMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PEPG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PEPG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

PepGen Inc. (PEPG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
1.7×

Cheaper than 52% of US stocks

EV / EBITDA
−1.4×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−75.5%

Higher than 16% of US stocks

Return on assets
−39.1%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PEPG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PEPGPepGen Inc.$206.8M
43
VOGXVogenx, Inc.$205.5M
1
DTILPrecision BioSciences, Inc.$205.1M
70
YDESYD Bio Ltd.$210.2M
53
KROSKeros Therapeutics, Inc.$199.1M
68
IVVDInvivyd, Inc.$212.4M
19
NERVMinerva Neurosciences, Inc.$213.4M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PepGen Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PEPG news & analysis

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Business Wire · 6 Aug 2026neutral

PepGen announced its financial results for the second quarter of 2026, along with recent corporate highlights. The announcement was made via a Business Wire release from the company's Boston headquarters.

Why it matters — PEPG watchers would care because quarterly financial results and corporate updates provide insight into the company's operational progress and financial health.

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

Business Wire · 6 Aug 2026positive

PepGen announced it will advance its investigational candidate PGN-EDODM1 into the highest dose cohort of the Phase 2 FREEDOM2-DM1 study, following a review by the Data Safety Monitoring Board (DSMB). The decision follows the DSMB's assessment of the ongoing trial.

Why it matters — For PepGen watchers, this decision signals that the DSMB review cleared advancement of the experimental DM1 therapy to a higher dose in the Phase 2 trial, a key step in its clinical development.

FAQ

Frequently asked questions about PEPG stock

What is the PEPG stock price forecast for 2026-2027?

The 8 Wall Street analysts covering PepGen Inc. have a median 12-month price target of $11, with estimates ranging from $2.5 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PEPG stock a buy right now?

Of the 8 analysts covering PepGen Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PepGen Inc. 43 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PEPG?

As at 15 Aug 2026, PepGen Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (81 of 100).

Will PEPG stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +251.2% from the last close, and Ticker Nerd's factor model ranks PepGen Inc. 43 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PEPG stock forecast for 2030?

No analyst covering PepGen Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PEPG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $20 over the next 12 months.

How has PEPG stock performed over the past year?

PepGen Inc. returned +131.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PepGen Inc. do?

PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapies.

What is the latest news on PEPG?

The most recent item we track (Business Wire, 6 Aug 2026): "PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights". PepGen announced its financial results for the second quarter of 2026, along with recent corporate highlights. The announcement was made via a Business Wire release from the company's Boston headquarters.

Company

About PepGen Inc.

PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapies. It advances the next generation of oligonucleotide therapeutics designed to transform the treatment of severe neuromuscular and neurologic diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1. The company focuses on proprietary platforms that enable enhanced delivery and efficacy of these therapies through clinical trials such as the FREEDOM and CONNECT studies. PepGen Inc. targets unmet needs in rare genetic disorders by innovating splicing correction and exon skipping mechanisms to address underlying disease causes. Its pipeline emphasizes precision medicine approaches for patients with limited treatment options. Founded in 2018 and headquartered in Boston, Massachusetts, PepGen Inc. operates within the health technology sector, contributing to advancements in biotechnology for neuromuscular conditions.

CEO Dr. James G. McArthur Ph.D. · 57 employees · United States · https://www.pepgen.com